BioNTech SE Q3 FY2025 earnings call

Vision and Strategy

• BioNTech's vision is to translate science into survival, building a global immunotherapy powerhouse. Focus on cancer as a systems problem, aiming for rationally designed combinations in cancer treatment.

Pipeline Highlights

• Pumitamig (formerly BNT327), a PD-L1 VEGF-A bispecific, with a broad registrational program in partnership with BMS. Progress in Q3 includes enrollment in global registrational trials in lung cancer and on track to initiate TNBC Phase III.
• mRNA cancer immunotherapies, including iNeST and FixVac, with Phase II updates showing relevance in earlier disease settings. BNT111 and Autogene cevumeran data presented, highlighting potential in adjuvant settings.
• AI Day underscores integration of AI in drug discovery and development.
• COVID-19 vaccine franchise, partnered with Pfizer, successfully launched variant-adapted vaccine.

Clinical Execution

• Pumitamig: Wave 1 focuses on foundational first-line indications in lung, NSCLC, TNBC. Wave 2 and 3 involve chemo-based signal-seeking studies and novel-novel combinations with ADCs. Q3 progress in small cell lung cancer registrational program and mono-agent profiling for ADC combinations.
• mRNA cancer immunotherapy: iNeST and FixVac trials ongoing, with data from melanoma and NSCLC studies informing development strategy.

For the three months ended September 30, 2025, total revenues were EUR 1.519 billion, an increase from EUR 1.245 billion in the same period of 2024. This was mainly driven by the recognition of USD 700 million from the BMS collaboration. Cost of sales was approximately EUR 148 million in Q3 2025 compared to EUR 179 million in Q3 2024, due to lower inventory write-downs. Research and development expenses were EUR 565 million in Q3 2025 vs. EUR 550 million in Q3 2024. SG&A expenses were EUR 148 million in Q3 2025 vs. EUR 150 million in Q3 2024. Other operating results were approximately negative EUR 705 million in Q3 2025 vs. negative EUR 355 million in Q3 2024, primarily influenced by a contractual dispute settlement. Net loss was EUR 29 million in Q3 2025 vs. net income of EUR 198 million in Q3 2024. Cash, cash equivalents, and security investments totaled EUR 16.7 billion at the end of Q3 2025.

Revenue Guidance

• Revised 2025 revenue guidance increased to $2.6 billion to $2.8 billion from the prior range of $1.7 billion to $2.2 billion, driven by the BMS collaboration recognition.

R&D Expenses

• Lowered 2025 R&D expense guidance to EUR 2 billion to EUR 2.2 billion from prior guidance, reflecting portfolio management and focus on key strategic programs.

SG&A and Capital Expenditure

• Reduced full-year SG&A expense guidance to $550 million to $650 million and capital expenditure for operating activities to $200 million to $250 million due to cost optimization and targeted investment in manufacturing.

Q: Tazeen Ahmad asked about the market opportunity for MSS CRC and first-line gastric cancer and how the product is differentiated from competition.

A: Özlem Türeci responded that both indications are high medical need, and the combination of VEGF-A and PD-L1 blocking has a biological rationale for improving clinical benefit.

Q: Terence Flynn inquired about the delay in BNT323 BLA filing and the R&D guidance change.

A: Ramón Zapata-Gomez said the R&D guidance reduction reflects portfolio management and focus on key programs. Özlem Türeci noted BNT323 BLA submission moved to 2026 due to FDA discussions and ongoing breast cancer study data needs.

Q: Daina Graybosch asked about the strategy of Establish and Elevate for Pumitamig.

A: Özlem Türeci explained the 3-wave strategy (Establish, Expand, Elevate) with parallel activities, including focus on chemo combinations for speed and ADC combination data generation.

Q: Nick Jennings asked about Phase II details for Pumitamig in TNBC and confidence in Phase III success.

A: Özlem Türeci stated they will present more efficacy, safety, and dose data at SABCS.

Q: Mohit Bansal questioned the bispecific's PD-1 component and OS benefit in lung cancer.

A: Ugur Sahin and Özlem Türeci discussed increasing confidence in the bispecific class, with preclinical and clinical data showing PFS and potential OS impact.

Q: Malcolm Hoffman inquired about revenue guidance contributions from COVID and BMS collaboration.

A: Ramón Zapata-Gomez explained COVID business is stable within expectations, and BMS revenue guidance update reflects the collaboration's USD 3.5 billion upfront and noncontingent cash payments.

Q: Josh Chazaro asked about Pumitamig's push into gastric cancer.

A: Ugur Sahin and Özlem Türeci mentioned emerging data and mechanistic rationale supporting the move into gastric cancer.

Q: Jay Olson asked about the governance structure of the BMS collaboration.

A: Özlem Türeci described a collaborative structure with a JSC, allowing flexibility in trials and exploitation of both partners' pipelines.